日本臨牀 70/増刊8 分子標的薬

出版社: 日本臨牀社
発行日: 2012-11-20
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 分子標的薬―がんから他疾患までの治癒をめざして―
電子書籍版: 2012-11-20 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

18,700 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

18,700 円(税込)

目次

  • 日本臨牀 70/増刊8 分子標的薬

    ―目次―

    特集 分子標的薬―がんから他疾患までの治癒をめざして―

    序 文:我が国におけるがん薬物療法の未来

    ?. 総 論    
     1. 分子標的治療薬とは  
     2. 分子標的薬の創薬・育薬  
     3. がん薬物療法の歴史
         ─殺細胞性抗悪性腫瘍薬(cytotoxic drug:CTX)から
          分子標的治療薬(molecular targeted drug: MTTC)
          への道─

    II. 基礎研究    
     1. 分子標的薬の作用機序・薬理作用    
     2. ゲノム・エピゲノム研究とバイオマーカー    
     3. ケミカルバイオロジーと構造生物学    
     4. 分子標的薬耐性化メカニズムの解明    
     5. 疾患領域別分子標的薬の基礎研究    
     6. 次世代分子標的薬の研究    

    III. 臨床研究    
     1. 腫瘍性疾患の分子標的薬    
     2. 非腫瘍性疾患の分子標的薬    
     3. 分子標的薬治療の予後と治療成績評価    

    IV. 特   論    
     1. 分子標的薬治療にみられる特殊な副作用と処置
     2. バイオシミラーについて
     3. 分子標的薬と薬剤トランスポーター
     4. 日本における分子標的薬の薬剤開発の課題と展望
     5. Pirin阻害剤TPh A  
     6. リン酸化特異的プロリン異性化酵素Pin1阻害小分子 
     7. 生理活性脂質アンタゴニストの抗血管新生作用
     8. がん分子標的としての
        C7orf24/γ-グルタミルシクロトランスフェラーゼ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
P.17 掲載の参考文献
7) 抗悪性腫瘍薬の臨床評価方法に関するガイドライン [http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/171101-b.pdf#search=]
8) Common Terminology Criteria for Adverse Events(CTCAE)Version 4.0.有害事象共通用語規準v4.0日本語訳JCOG版(略称:CTCAE v4.0-JCOG).[http://www.jcog.jp/doctor/tool/CTCAEv4J_20100911.pdf]
9) 固形がんの治療効果判定のための新ガイドライン(RECISTガイドライン)-改訂版version 1.1-日本語訳JCOG版ver.1.0. [http://www.jcog.jp/doctor/tool/RECISTv11J_20100810.pdf]
11) マイクロドーズ臨床試験の実施に関するガイダンス.[http://www.mhlw.go.jp/topics/bukyoku/isei/chiken/dl/080705.pdf]
12) 上坂浩之:医薬の世界同時開発と多地域試験.保険医療科学60:18-26,2011.
13) 国際共同治験に関する基本的考え方(案)について.[http://www.pmda.go.jp/guide/hyougikai/18/H190306gijishidai/file/chiken-shiryo6.pdf#search=]

II 基礎研究

P.30 掲載の参考文献
P.34 掲載の参考文献
P.39 掲載の参考文献
P.44 掲載の参考文献
4) Nowell PC,Hungerford DA:A minute chromosome in human chronic granulocytic leukemia.Science 132:1497-1499,1960.
9) Deininger MWN,et al:The molecular biology of chronic myeloid leukemia.Blood 96:3343-3356,2000.
P.51 掲載の参考文献
P.55 掲載の参考文献
P.62 掲載の参考文献
P.66 掲載の参考文献
10) Chen Z,et al:A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.Nature 483:613-617,2012.
11) 中村鑑斗,藤田直也:増殖シグナル伝達.日本臨牀 67(増刊号1):66-70,2009.
P.70 掲載の参考文献
P.75 掲載の参考文献
P.83 掲載の参考文献
1) Kim HJ,Bae SC:Histone deacetylase inhibitors:molecular mechanisms of action and clinical trials as anti-cancer drugs.Am J Transl Res 3:166-179,2011.
13) Furumai R,et al:FK228(depsipeptide)as a natural prodrug that inhibits class I histone deacetylases.Cancer Res 62:4916-4921,2002.
P.89 掲載の参考文献
1) 岩井一宏:ユビキチン修飾系の多彩な機能.細胞工学 29:1190-1194,2010.
2) 村田茂穂:プロテアソームによるタンパク質分解制御.細胞工学 29:1216-1221,2010.
7) Palombella VJ,et al:The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB.Cell 78:773-785,1994.
10) Hideshima T,et al:Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells.Blood 114:1046-1052,2009.
P.96 掲載の参考文献
5) Esteller M,et al:A gene hypermethylation profile of human cancer.Cancer Res 61(8):3225-3229,2001.
P.101 掲載の参考文献
1) Azuma K,Inoue S:Genomic and non-genomic actions of estrogen:recent developments.BioMol Concepts.(in press)
14) Mouridsen H,et al:Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.J Clin Oncol 21:2101-2109,2003.
P.107 掲載の参考文献
1) 野村雍夫:乳癌のホルモン療法6 アロマターゼ阻害剤,(全体にわたって参照),医学図書出版,2007.
3) Honma N,et al:Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3β,17β-diol.Cancer Sci 102(10):1848-1854,2011.
5) Geisler J,et al:In vivo inhibition of aromatization by exemestane,a novel irreversible aromatase inhibitor,in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093,1998.
P.112 掲載の参考文献
12) Naito T,et al:Antagonistic interactions between Ikaros and the chromatin remodeler Mi-2β determine silencer activity and Cd4 gene expression.Immunity 27:723-734,2007.
14) Williams CJ,et al:The chromatin remodeler Mi-2β is required for CD4 expression and T cell development.Immunity 20:719-733,2004.
15) Yoshida T,et al:The role of the chromatin remodeler Mi-2β in hematopoietic stem cell self-renewal and multilineage differentiation.Genes Dev 22:1174-1189,2008.
P.117 掲載の参考文献
P.124 掲載の参考文献
P.129 掲載の参考文献
P.134 掲載の参考文献
P.139 掲載の参考文献
P.143 掲載の参考文献
P.148 掲載の参考文献
2) 河上裕:がん細胞と免疫系の相互作用の分子機構とその制御.実験医学 27:2170-2175,2009.
P.153 掲載の参考文献
P.157 掲載の参考文献
6) Yiotakis A,Dive V:Third-generation MMP inhibitors:recent advances in the development of highly selective inhibitors.In:The Cancer Degradome:Proteases and Cancer Biology(ed by Edwards D,et al),p787-810,Springer,New York,2008.
P.163 掲載の参考文献
P.168 掲載の参考文献
2) Shultz LD,et al:Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.J Immunol 154:180-191,1995.
4) Tanaka S,et al:J Immunol,2012.May 18[Epub ahead of print]
P.174 掲載の参考文献
21) Parker CJ,Forester J:Wintrobe's Clinical Hematology,Vol 1,Chapter 44 Mechanisms of immune destruction of erythrocytes(10th edition),p1191-1209,Williams & Winkins,Baltimore,1999.
P.180 掲載の参考文献
P.184 掲載の参考文献
1) Nagano Y,Kojima Y:Pouvoir immunisant du virus vaccinal inactive par des rayons ultraviolets.C R Seances Soc Biol Fil 148:1700-1702,1954.
11) Sin WX,et al:Activation and regulation of interferon-beta in immune resposes.Immunol Res,2012.[Epub ahead of print]
P.190 掲載の参考文献
9) Butler DM,et al:Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures.Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.Eur Cytokine Netw 6:225-230,1995.
13) Lipsky PE,et al:Infliximab and methotrexate in the treatment of rheumatoid arthritis Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.N Engl J Med 343:1594-1602,2000.
P.206 掲載の参考文献
P.211 掲載の参考文献
P.217 掲載の参考文献
12) Ishida T,et al:Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma:its close association with skin involvement and unfavorable outcome.Clin Cancer Res 9:3625-3634,2003.
P.224 掲載の参考文献
6) Banerjee A,et al:p38 MAPK inhibitors,IKK2 inhibitors,and TNFα inhibitors in COPD.Curr Opin Pharmacol 12:1-6,2012.
P.229 掲載の参考文献
P.235 掲載の参考文献
5) Takayama K,et al:Thromboxane A2 and prostaglandin F2α mediate inflammatory tachycardia.Nat Med 11:562-566,2005.
P.239 掲載の参考文献
6) Yamamoto M,et al:Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ. Nature 430:218-222,2004.
7) Kayama H,et al:Class-specific regulation of pro-inflammatory genes by MyD88 pathways and IκBζ. J Biol Chem 283:12468-12477,2008.
8) Charo IF,et al:Macrophage polarization and insulin resistance:PPARγ in control.Cell Metab 6:96-98,2007.
P.245 掲載の参考文献
P.249 掲載の参考文献
11) Nakajima T,et al:Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcε receptor I cross-linking:an interspecies comparison.Blood 100:3861-3868,2002.
14) Okumura S,et al:Fcε RI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells.J Allergy Clin Immunol 115:272-279,2005.
P.255 掲載の参考文献
5) Peters JM,et al:Dissecting the role of peroxisome proliferator-activated receptor-β/δ(PPARβ/δ)in colon,breast,and lung carcinogenesis.Cancer Metastasis Rev 30:619-640,2011.
6) Cariou B,et al:Thiazolidinediones and PPARγ agonists:time for a reassessment.Trends Endocrinol Metab 23:205-215,2012.
7) Hiukka A,et al:PPARα:an emerging therapeutic target in diabetic microvascular damage.Nat Rev Endocrinol 6:454-463,2010.
15) Choi JH,et al:Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.Nature 477:477-481,2011.
P.261 掲載の参考文献
1) Derynck R,Miyazono K:The TGF-β Family,Cold Spring Harbor Laboratory Press,Cold Spring Harbor,2008.
3) Ikushima H,Miyazono K:TGF-β signaling transduction spreading to a wider field:abroad variety of mechanisms for context-dependent effects of TGF-β.Cell Tissue Res 347:37-49,2012.
5) Heldin CH,et al:Mechanism of TGF-β signaling to growth arrest,apoptosis,and epithelial-mesenchymal transition.Curr Opin Cell Biol 21:166-176,2009.
6) Xu J,et al:TGF-β-induced epithelial to mesenchymal transition.Cell Res 19:156-172,2009.
7) Gorelik L,Flavell RA:Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells.Nat Med 7:1118-1122,2001.
8) Ghiringhelli F,et al:CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner.J Exp Med 202:1075-1085,2005.
9) Komuro A,et al:Diffuse-type gastric carcinoma:progression,angiogenesis, and transforming growth factor β signaling.J Natl Cancer Inst 101:592-604,2009.
10) Ikushima H,Miyazono K:TGF-β signaling:a complex web in cancer progression.Nature Rev Cancer 10:413-424, 2010.
11) Tang B,et al:Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.Cancer Res 67:8643-8652,2007.
12) Penuelas S,et al:TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.Cancer Cell 15:315-327,2009.
13) Naka K,et al:TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.Nature 463:676-680,2010.
14) Pohlers D,et al:TGF-β and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 1792:746-756,2009.
15) Hawinkels LJ,Ten Dijke P:Exploring anti-TGF-β therapies in cancer and fibrosis.Growth Factors 29:140-152,2011.
16) Meulmeester E,Ten Dijke P:The dynamic role of TGF-β in cancer.J Pathol 223:205-218,2011.
P.267 掲載の参考文献
1) 冨山佳昭:先天性血小板機能異常症-受容体異常症.別冊・医学のあゆみ 血液疾患-state of arts Ver.3(坂田洋一,小澤敬也編),p728-732,医歯薬出版,2005.
4) Kamae T,et al:Critical role of ADP interaction with P2Y12 receptor in the maintenance of αIIbβ3 activation:association with Rap1B activation.J Thromb Haemost 4:1379-1387,2006.
P.271 掲載の参考文献
8) 宮崎洋:トロンボポエチン(TPO).サイトカイン・ケモカインのすべて(第三版改定新版)(笠倉新平,松島鋼治編),p315-326,日本医学館,2004.
P.276 掲載の参考文献
1) 赤池孝章:活性酸素のシグナル伝達機能-その生理機能の再発見と酸化ストレス研究の新展開-.実験医学 27:2320-2327,2009.
11) Fang J,et al:In vivo antitumor activity of pegylated zinc protoporphyrin:targeted inhibition of heme oxygenase in solid tumor.Cancer Res 63:3567-3574,2003.
P.280 掲載の参考文献
P.286 掲載の参考文献
1) Ding L,et al:Somatic mutations affect key pathways in lung adenocarcinoma.Nature 455:1069-1075,2008.
3) Wood LD,et al:The genomic landscapes of human breast and colorectal cancers.Science 318:1108-1113,2007.
P.292 掲載の参考文献
5) Xu W,et al:Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.Cancer Cell 19(1):17-30,2011.
P.297 掲載の参考文献
1) Davies H,et al:Mutations of the BRAF gene in human cancer.Nature 417(6892):949-954,2002.
P.306 掲載の参考文献
3) Secrist JP,et al:HDAC inhibitors for the treatment of cancer.Curr Opin Investig Drugs 4:1422-1427,2003.
P.315 掲載の参考文献
1) 水上民夫:がん分子標的薬開発状況に関する情報.文部科学省新学術領域研究「がん研究分野の特性等を踏まえた支援活動」化学療法基盤支援活動[http://scads.jfcr.or.jp/db/table.html].
2) 水上民夫ほか:がんをとりまく医療環境-抗がん剤開発の環境変化を中心として-.医学のあゆみ 222:965-970,2007.
3) 水上民夫:がんにおける新しい創薬の展開.癌と化学療法 35:2293-2300,2008.
10) 山下順範,水上民夫:酵母宿主のフォワードケミカルゲノミクスによる抗癌剤創薬の展開.化学と生物 45:2-4,2007.
18) Perkins E,et al:Novel inhibitors of poly(ADP-ribose)polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.Cancer Res 61:4175-4183,2001.
P.319 掲載の参考文献
15) Wu H,et al:Structure of the human κ-opioid receptor in complex with JDTic.Nature 485:327-332,2012.
P.325 掲載の参考文献
5) Weggen S,et al:A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity.Nature 414:212-216,2001.
6) Oehlrich D,et al:γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.J Med Chem 54:669-698,2011.
8) Sato C,et al:Structure of the catalytic pore of γ-secretase probed by the accessibility of substituted cysteines.J Neurosci 26:12081-12088,2006.
9) Sato C,et al:The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the γ-secretase.J Neurosci 28:6264-6271,2008.
10) Takagi S,et al:Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the γ-secretase.J Neurosci 30:15943-15950,2010.
11) Ohki Y,et al:Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 30:4815-4824,2011.
12) Hayashi I,et al:Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin.Oncogene 31:787-798,2012.
14) Takeo K,et al:Contribution of the γ-secretase subunits to the formation of catalytic pore of presenilin 1 protein.J Biol Chem 287:25834-25843,2012.
P.330 掲載の参考文献
11) 平成23年度ターゲットタンパク研究プログラム公開シンポジウム「インシリコスクリーニング技術のターゲットタンパク質への応用」 [http://www.youtube.com/watch?v=AxI618hY_ug&list=UU3p9D9nWAQ2z9COGkvalQ9w&index=13&feature=plcp]
P.334 掲載の参考文献
2) 三宅秀明,藤澤正人:疾患別分子標的薬治療の現状と今後の展望-泌尿器癌(腎細胞癌を中心に).日本臨牀 68:1871-1875,2010.
P.339 掲載の参考文献
P.345 掲載の参考文献
P.350 掲載の参考文献
8) Bocangel D,et al:p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase(MGMT)via interaction with Sp1 transcription factor.Anticancer Res 29:3741-3750,2009.
P.358 掲載の参考文献
1) Huggins C,Hodges CV:Studies on prostatic cancer:I.The effect of castration,of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate.Cancer Res 1:293-297,1941.
14) de Bono JS,et al;COU-AA-301 Investigators:Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med 364:1995-2005,2011.
P.363 掲載の参考文献
P.370 掲載の参考文献
P.376 掲載の参考文献
P.382 掲載の参考文献
P.387 掲載の参考文献
1) Mount DW:バイオインフォマティクス第2版,メディカル・サイエンス・インターナショナル,2005.
13) http://www.santaris.com/news/2011/11/05/santaris-pharma-phase-2a-data-miravirsen-shows-dose-dependent-prolonged-viral-reduct
14) Fang M,et al:The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease.Toxicol Lett 209:94-105,2012.
P.391 掲載の参考文献
3) Leung L,Cahill CM:TNF-α and neuropathic pain-a review.J Neuroinflammation 7:27,2010.
5) Smith HS,et al:Painful rheumatoid arthritis.Pain Physician 14:E427-458,2011.
8) Pillarisetti S:Targeting interleukin-1β for pain.CNS Neurol Disord Drug Targets 10:571-575,2011.
P.397 掲載の参考文献
P.401 掲載の参考文献
P.407 掲載の参考文献
P.412 掲載の参考文献
P.416 掲載の参考文献

III 臨床研究

P.426 掲載の参考文献
P.432 掲載の参考文献
3) Ang KK,et al:Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.Cancer Res 62:7350-7356,2002.
5) Huang SM,et al:Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinomas of the head and neck.Cancer Res 59:1935-1940,1999.
P.437 掲載の参考文献
1) 加藤健:食道がん.新臨床腫瘍学 改訂第2版(日本臨床腫瘍学会編集),p471-482,南光堂,2009.
4) Kitagawa Y,et al:Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma.Clin Cancer Res 2:909-914,1996.
P.441 掲載の参考文献
P.445 掲載の参考文献
P.450 掲載の参考文献
P.455 掲載の参考文献
P.462 掲載の参考文献
7) 日本肝臓学会:肝癌診療マニュアル第2版,医学書院,2010.
8) 日本肝臓学会:科学的根拠に基づく肝癌診療ガイドライン2009年版,金原出版,2009.
P.467 掲載の参考文献
3) Yanagisawa A,et al:Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation.Cancer Res 53:953-956,1993.
7) Uwagawa T,et al:Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.Am J Clin Oncol,2011.[Epub ahead of print]
P.473 掲載の参考文献
P.478 掲載の参考文献
16) Parker C,et al:Overall survival benefit of radium-223 chloride(apharadin)in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer(CRPC):a phase III randomized trial(ALSYMPCA).Presented at:European Multidisciplinary Cancer Congress;September 23-27,2011;Stockholm,Sweden.Abstract 1LBA. [http://kundeweb.aggressive.no/users/algeta2.no/filer/1109%20ESMO%20presentation%20v5.pdf]
P.485 掲載の参考文献
1) 腎癌診療ガイドライン2007年版,金原出版,2007.
2) 腎癌診療ガイドライン2011年版,金原出版,2011.
5) 植村天受ほか:日本人転移性腎癌におけるaxitinibの有効性・安全性の検討.日泌会誌 103:332 Abst.p-424,2012.
6) http://www.clinicaltrials.gov/ct2/show/NCT00720941
7) http://www.clinicaltrials.gov/ct2/show/NCT01223027
8) http://www.clinicaltrials.gov/ct2/show/NCT01030783
9) http://www.clinicaltrials.gov/ct2/show/NCT00329628
10) http://www.clinicaltrials.gov/ct2/show/NCT00631371
11) http://www.clinicaltrials.gov/ct2/show/NCT00732914
12) http://www.clinicaltrials.gov/ct2/show/NCT00332020
13) http://www.sogug.es/proyectos_cientificos/cancer_renal.aspx
14) http://www.clinicaltrials.gov/ct2/show/NCT01481870
17) Porta C,et al:Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer:a clinical review.Eur J Clin Med Oncol,2010. [http://www.slm-oncology.com]
P.490 掲載の参考文献
1) Cytotoxic chemotherapy for metastatic melanoma,UpToDate [http://www.uptodate.com].
2) NCCN Guidelines Version 3.2012,Melanoma [http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf]
6) 高田実:進行期メラノーマの最新治療.皮膚科の臨床 53:401-407,2011.
P.495 掲載の参考文献
1) 土井隆一郎ほか:外科治療.膵・消化管神経内分泌腫瘍(NET)診断治療 実践マニュアル(今村正之総監修),p108-147,総合医学社,2011.
3) Bosman FT,et al:WHO Classification of Tumours of the Digestive System(World Health Organization Classification of Tumours),IARC Press,Lyon,2010.
7) Yao JC,et al;RAD001 in Advanced Neuroendocrine Tumors,Third Trial(RADIANT-3)Study Group:Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med 364:514-523,2011.
9) 坪内博仁ほか:免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-.肝臓 50:38-42,2009.
12) Yao JC,et al:Targeting vascular endothelial growth factor in advanced carcinoid tumor:a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon-α2b.J Clin Oncol 26:1316-1323,2008.
13) Pavel M:Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors.Neuroendocrinology,2012.[Epub ahead of print]
14) 伊藤鉄英ほか:日本における膵内分泌腫瘍の疫学.膵臓 23:654-659,2008.
15) National Comprehensive Cancer Network:NCCN Guidelines Neuroendocrine Tumors,version 1,2011.
P.499 掲載の参考文献
4) Petersdorf S,et al:Preliminary Results of Southwest Oncology Group Study S0106:An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.ASH Annual Meeting.Vol 114;2009:#790.
6) Castaigne S,et al:Fractionated Doses of Gemtuzumab Ozogamicin(GO)Combined to Standard Chemotherapy(CT)Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old:A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association(ALFA).ASH Annual Meeting.Vol 118;2011:#6.
11) Bories P,et al:Efficacy of Frontline 5-Azacytidine in Older AML Patient Unfit for Chemotherapy.ASH Annual Meeting.Vol 118;2011:#2614.
12) Serrano J,et al:5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly(>60 years)Acute Myeloid Leukemia Patients.A Retrospective Analysis.ASH Annual Meeting.Vol 118;2011:#2612.
13) Cortes J,et al:A Phase II Open-Label,Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia:Updated Interim Results.ASH Annual Meeting.Vol 118;2011:#2576.
P.506 掲載の参考文献
3) O'Brien SG,et al:International randomized study of interferon versus STI571(IRIS)7-year follow-up:sustained survival,low rate of transformation and increased rate of major molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib.Blood 112:186a,2008.
5) Saglio G,et al:Nilotinib versus imatinib in patients(pts)with newly diagnosed Philadelphia chromosome-positive(Ph+)chronic myeloid leukemia in chronic phase(CML-CP):ENESTnd 36-Month(mo)follow-up.Blood 118:452a,2011.
9) Shar NP,et al:Dasatinib dose-optimization in chronic phase chronic myeloid leukemia:two-year data from CA 180-034 show equivalent long-term efficacy and improved safety with 100mg once daily dose.Blood 112:3225a,2008.
11) Cortes JE,et al:Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia-BELA trial:24-month follow-up.Blood 118:455a,2011.
12) Cortes JE,et al:A phase 1 trial of oral ponatinib(AP24534)in patients with refractory chronic myelogenous leukemia(CML)and other hematologic malignancies:emerging safety and clinical response findings.Blood 116:210a,2010.
P.512 掲載の参考文献
6) Gore SD,et al:Changes in promoter methylation and gene expression in patients with MDS-AML treated with 5-azacitidine and sodium phenylbutylate.ASH 2004,Abstract 469.
P.517 掲載の参考文献
P.522 掲載の参考文献
P.528 掲載の参考文献
P.532 掲載の参考文献
P.538 掲載の参考文献
P.544 掲載の参考文献
11) Merrill JT,et al:Safety profile and clinical activity of sifalimumab,a fully human anti-interferon α monoclonal antibody,in systemic lupus erythematosus:a phase I,multicenter,double-blind randomized study.Ann Rheum Dis 70:1905-1913,2011.
P.548 掲載の参考文献
1) Presta LG,et al:Humanization of an antibody directed against IgE.J Immunol 151:2623-2632,1993.
P.554 掲載の参考文献
1) 佐野栄紀:尋常性乾癬:病態と治療の進歩.日皮会誌 121:839-844,2011.
12) http://www.Clinicaltrials.Bov/ct2/results?Term=psoriasis
P.559 掲載の参考文献
P.568 掲載の参考文献
11) Gattorno M,et al:Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome(TRAPS). (Abstract)EULAR 2012(Berlin).
12) Goldbach-Mansky R,et al:Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.N Engl J Med 355:581-592,2006.
17) Imagawa T,et al:Safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome:24-week results from an open-label,phase-3 pivotal study.Clin Exp Rheumatol.(in press)
P.572 掲載の参考文献
10) Louis E,et al;Groupe D’etudes Therapeutiques Des Affections lnflammatoires Digestives:Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.Gastroenterology 142(1):63-70,2012.
P.577 掲載の参考文献
2) Fiore AE,et al;Centers for Disease Control and Prevention(CDC):Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices(ACIP).MMWR Recomm Rep 60(1):1-24,2011.
8) Centers for Disease Control and Prevention(CDC):Oseltamivir-resistant 2009 pandemic influenza A(H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina,2009. MMWR Morb Mortal Wkly Rep 58:969-972,2009.
P.582 掲載の参考文献
2) McIntosh K:Respiratory Syncytial Virus,in Viral Infections of Human(ed by Evans AS,Kaslow RA),p691-711,Plenum Publishing Co,New York,1997.
5) 武内可尚ほか:未熟児のRSウイルス感染に関する前方視的臨床疫学調査.日小児会誌 107:898-904,2003.
9) 山口文佳,楠田聡:新生児感染症up to date;RSウイルス.周産期医学 41:399-404,2011.
P.588 掲載の参考文献
P.592 掲載の参考文献
P.595 掲載の参考文献
P.601 掲載の参考文献
P.607 掲載の参考文献
P.612 掲載の参考文献
P.616 掲載の参考文献
3) Burks TN,Cohn RD:Role of TGF-β signaling in inherited and acquired myopathies.Skelet Muscle 1:19,2011.
5) Taniguti AP,et al:Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin,a TGF-β1 blocker.Muscle Nerve 43:82-87,2011.
P.621 掲載の参考文献
3) Narkar VA,et al:AMPK and PPARδ agonists are exercise mimetics.Cell 134:405-415,2008.
4) Bays HE,et al:MBX-8025,a novel peroxisome proliferator receptor-δ agonist:lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.J Clin Endocrinol Metab 96:2889-2897,2011.
P.626 掲載の参考文献
1) 折茂肇:骨粗鬆症の予防と治療ガイドライン2011年版,ライフサイエンス出版,2011.
P.643 掲載の参考文献
1) 中江公裕ほか:わが国における視覚障害の現状.厚生労働科学研究研究費補助金 難治性疾患克服研究事業 網膜脈絡膜・視神経萎縮症に関する研究 平成17年度 総括・分担研究報告書,p263-267,2006.
11) Michaelson IC:The mode of development of the vascular system of the retina,with some observations on its significance for certain retinal diseases.Trans Ophthalmol Soc UK 68:137-181,1948.
16) Murata T,et al:The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas.Lab Invest 74:819-825,1996.
23) Mitchell P,et al:The RESTORE study:ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.Ophthalmology 118:615-625,2011.
P.651 掲載の参考文献
3) Baffi J,et al:Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor.Invest Ophthalmol Vis Sci 41:3582-3589,2000.
8) ペガプタニブナトリウム共同試験グループ:脈絡膜新生血管を伴う加齢黄斑変性を対象としたペガプタニブナトリウム1年間投与試験.日眼会誌 112:590-600,2008.
P.656 掲載の参考文献
1) 西條長宏:分子標的治療の潮流.医薬ジャーナル 46:2453-2459,2010.
2) 西條長宏:増殖のドライビングフォースの遺伝子構成変化に対する分子標的治療は併用療法の対象外か? 医薬ジャーナル 47:1405-1409,2011.
3) 西條長宏:抗悪性腫瘍薬併用療法の現状と展望.医薬ジャーナル 47:1351,2011.
4) 西條長宏:がん分子標的治療の現状と課題-臨床試験における評価を含めて.Progress in Medicine 31:2509-2536,2011.
5) 西條長宏:悪性腫瘍に対する分子標的治療.アニムス 70:25-30,2012.
7) 西條長宏:血管新生阻害作用による治療.日本臨牀 68:1007-1113,2010.
8) 西條長宏:血管新生阻害薬-ベバシズマブについて適正な投与量,投与スケジュール,副作用,コストベネフィット.腫瘍内科 9:471,2012.
P.662 掲載の参考文献
1) den Broeder AA,et al:Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis:effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.Ann Rheum Dis 61:311-318,2002.
2) Mugnier B,et al:Polymorphism at position-308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis.Arthritis Rheum 48:1849-1852,2003.
3) Marotte H,et al:Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab:link to clinical response. Arthritis Res Ther 7:R149-R155,2005.
4) Braun-Moscovici Y,et al:Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis.J Rheumatol 33:497-500,2006.
6) Mancarella L,et al:Good clinical response,remission,and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers:the GISEA study.J Rheumatol 34:1670-1673,2007.
7) Guis S,et al:Influence of-308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis.Arthritis Rheum 57:1426-1430,2007.
16) McGeough CM,et al:Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.Rheumatol Int 32:1647-1653,2012.
17) Koga T,et al:Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.Clin Exp Rheumatol 29(5):811-815,2011.
24) Sekiguchi N,et al:Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNFα monoclonal antibody,infliximab.Rheumatology(Oxford) 47:780-788,2008.
25) Koczan D,et al:Molecular discrimination of responders and nonresponders to anti-TNFα therapy in rheumatoid arthritis by etanercept.Arthritis Res Ther 10:R50,2008.
28) Saech J,et al:A decrease in neutrophil counts following a single infusion of tocilizumab is predictive of low disease activity and remission after 24 weeks.Ann Rheum Dis 69(Suppl 3):499,2010.
31) Nishimoto N:Gene expression profile in peripheral blood cells at baseline predicts tocilizumab responsiveness of patients with rheumatoid arthritis.Ann Rheum Dis 68(Suppl 3):134,2009.
33) Gottenberg JE,et al:Positivity for RF/anti-CCP is associated with a better response to abatacept:data from the "orencia and rheumatoid arthritis" (ORA)registry.Ann Rheum Dis 70(Suppl 3):74,2011.
P.668 掲載の参考文献

IV 特論

P.676 掲載の参考文献
4) Yamazaki N,Muro K:Clinical management of EGFRI dermatologic toxicities:the Japanese perspective.Oncology(Williston Park) 21(11 Suppl 5):27-28,2007.
12) Barnard K:Viewpoint:an explanation for the cardiovascular effects of bevacizumab and rofecoxib? Circulation 114(19):f173-175,2006.
16) 安藤稔:【分子標的治療薬による特異的な副作用とその対策】 腎毒性 蛋白尿と高血圧.癌と化学療法 35(10):1649-1653,2008.
20) 岸田修二:【分子標的治療薬による特異的な副作用とその対策】 癌分子標的治療薬による中枢神経合併症.癌と化学療法 35(10):1659-1664,2008.
21) 伊藤泰広:【脳炎・脳症 診断と治療の進歩】 診断と治療 特異な脳炎・脳症 Reversible posterior leukoencephalopathy syndrome(RPLS).日内会誌 95(7):1297-1304,2006.
P.687 掲載の参考文献
2) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:quality issues;EMEA/CHMP/BWP/49348/2005(22 Feb.2007).
4) 「バイオ後続品の品質・安全性・有効性確保のための指針」(平成21年3月4日付薬食審査発第0304007号).
8) FDA Draft Guideline:Guidance for Industry Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product,2012.
9) ICH Q6B:生物薬品(バイオテクノロジー応用医薬品/生物起源由来医薬品)の規格及び試験方法の設定,2001.
10) Guidelines on evaluation of similar biotherapeutic products(SEBs).WHO,2009. [http://www.biosimilars.ca/docs/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf]
11) Guidance for Sponsors:Information and submission requirements for subsequent entry biologics(SEBs),Health Canada,2010.
13) Draft guideline;guideline on production and quality control of monoclonal antibodies and related substances.EMEA/CHMP/BWP/157653/2007,2007.
16) http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON033504&RevisionSelectionMethod=LatestReleased
P.694 掲載の参考文献
8) Yamakawa Y,et al:Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.Ther Drug Monit 33(2):244-250,2011.
P.702 掲載の参考文献
1) http://www.horei.mhlw.go.jp/hourei/doc/tsuchi/171101-b.pdf
2) 土井俊彦:施設側からみたわが国におけるFIH試験の問題点と解決策.腫瘍内科 9(3):350-353,2012.
4) 水谷民夫:承認された分子標的抗がん剤一覧2012.JAMTTC News Letter 16(1):8-9,2012.
7) http://mli.nih.gov/mli/mlpcn/
8) http://dctd.cancer.gov/CurrentResearch/ChemicalBioConsortium.htl
9) http://next.cancer.gov/default.htm
11) 矢守隆夫ほか:制がん候補物質のスクリーニング成績(第13報).癌と化学療法 37(Suppl 1):1-158,2010.
14) 開発段階別化合物数と承認取得数.Data Book 2011,p46,日本製薬工業協会,2011.
15) http://www.ctrp.mext.go.jp/
16) http://tr.mext.go.jp/
17) http://www.tri-kobe.org/news/pdf/hashiwatashi_20120302.pdf
19) 武部直子:米国National Cancer Instituteの実験治療プログラムが産官学連携に果たす役割.腫瘍内科 9(3):359-362,2012.
20) http://www.mhlw.go.jp/shingi/2010/01/dl/s0119-10a.pdf
21) http://www.mhlw.go.jp/stf/shingi/2r9852000001xhli.pdf
P.707 掲載の参考文献
P.716 掲載の参考文献
P.722 掲載の参考文献
4) 米須清明:スフィンゴシン-1-リン酸受容体アンタゴニストの抗血管新生作用.バイオサイエンスとインダストリー 68:117-119,2010.
10) Shankar G:Selective disruption of tumor vessel architecture via inhibition of S1P1 with a novel small molecule,XL541.Proc Am Assoc Cancer Res(AACR) 50:abstract 3394,2009.
P.726 掲載の参考文献
8) Uejima D,et al:Involvement of cancer biomarker C7orf24 in the growth of human osteosarcoma.Anticancer Res 31:1297-1305,2011.

最近チェックした商品履歴

Loading...